Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Dyne Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
DYN
Nasdaq
8731
https://dyne-tx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Dyne Therapeutics Inc
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
- Mar 27th, 2024 8:05 pm
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
- Mar 27th, 2024 12:30 pm
Dyne Therapeutics Announces CEO Transition
- Mar 25th, 2024 11:30 am
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
- Mar 13th, 2024 11:30 am
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...
- Mar 7th, 2024 6:19 pm
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Mar 5th, 2024 12:30 pm
CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN)
- Mar 2nd, 2024 5:00 am
14 Stocks With Heavy Insider Buying In 2024
- Feb 29th, 2024 8:02 am
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
- Feb 14th, 2024 9:15 pm
Dyne Therapeutics to Present at February Investor Conferences
- Feb 1st, 2024 12:30 pm
Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)
- Jan 27th, 2024 4:01 am
7 Speculative Stocks to Double Your Money THIS Year
- Jan 23rd, 2024 3:14 am
Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap decline as longer-term profits stay in the green
- Jan 14th, 2024 1:52 pm
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Jan 11th, 2024 9:05 pm
CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN)
- Jan 5th, 2024 2:02 pm
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 5th, 2024 12:30 pm
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
- Jan 5th, 2024 3:46 am
Today’s Stock Market Movers: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More
- Jan 4th, 2024 9:37 pm
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Jan 3rd, 2024 9:25 pm
Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results
- Jan 3rd, 2024 7:46 pm
Scroll